{"id":"tezepelumab-apfs","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Musculoskeletal pain"}]},"_chembl":{"chemblId":"CHEMBL3707229","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking TSLP, tezepelumab prevents the activation of immune cells and the release of pro-inflammatory cytokines, which are key drivers of allergic inflammation. This mechanism of action is thought to be responsible for the therapeutic effects of tezepelumab in treating severe asthma and other allergic diseases.","oneSentence":"Tezepelumab is a monoclonal antibody that targets and blocks the activity of thymic stromal lymphopoietin (TSLP), a cytokine involved in the initiation of allergic inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:11.159Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe asthma"},{"name":"Eosinophilic esophagitis"}]},"trialDetails":[{"nctId":"NCT05651841","phase":"PHASE3","title":"REVErsing Airway Remodelling With Tezepelumab","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2023-03-27","conditions":"Airway Remodelling, Asthmatic","enrollment":90},{"nctId":"NCT03968978","phase":"PHASE3","title":"Tezepelumab Home Use Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-05-21","conditions":"Asthma","enrollment":216},{"nctId":"NCT03989544","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics of Tezepelumab After Being Delivered by an Accessorized Pre Filled Syringe or Autoinjector Compared With Vial and Syringe in Healthy Adult Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-06-19","conditions":"Asthma","enrollment":315}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tezepelumab (APFS)","genericName":"Tezepelumab (APFS)","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tezepelumab (APFS) is an antibody that inhibits thymic stromal lymphopoietin, a protein involved in the development of asthma and airway remodelling. It is being studied as a potential treatment for asthma and airway remodelling, among other conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}